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Abstract
G protein-coupled receptors (GPCRs) are essential mediators of cellular signaling and important 
targets of drug action. Of the approximately 350 non-olfactory human GPCRs, more than 100 are 
still considered “orphans” as their endogenous ligand(s) remain unknown. Here, we describe a 
unique open-source resource that provides the capacity to interrogate the druggable human GPCR-
ome via a G protein-independent β-arrestin recruitment assay. We validate this unique platform at 
more than 120 non-orphan human GPCR targets, demonstrate its utility for discovering new 
ligands for orphan human GPCRs, and describe a method (PRESTO-TANGO; Parallel Receptor-
ome Expression and Screening via Transcriptional Output - TANGO) for the simultaneous and 
parallel interrogation of the entire human GPCR-ome.
G protein-coupled receptors (GPCRs) are proteins with seven transmembrane helices 
capable of transducing a wide variety of extracellular stimuli into intracellular signals, 
mediated by G proteins of four groups, Gs, Gi, G12 or 13 or Gq, as well as arrestins and other 
effectors1. The human genome encodes more than 350 different non-olfactory GPCRs, as 
well as a similar number of olfactory GPCRs2–4. In addition to their roles as signal 
transducers, GPCRs are the targets for more than one-third of currently prescribed 
medications5, 6. Approximately one-third of the non-olfactory GPCRs in the human genome 
are “orphan” GPCRs, i.e., their endogenous or natural ligands are unknown2–4, while many 
more are inadequately interrogated with respect to their ligands. Thus, much of the 
druggable GPCR-ome – like other drug target families such as the kinome7, represents ‘dark 
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matter’ of the human genome. As many of these sparsely annotated GPCRs will likely 
represent fruitful future therapeutic targets, identifying drug-like chemical leads for the 
entire family of druggable GPCRs represents a major goal for chemical biology. 
Unfortunately, interrogating the druggable GPCR-ome en masse in a parallel and 
simultaneous fashion is currently technologically and economically unfeasible.
The difficulty in screening the entire druggable GPCR-ome in parallel is due mainly to the 
inherent diversity of signal transduction cascades, rendering attempts at parallel profiling 
challenging. Thus, for instance, functional assays for the identification of agonists at orphan 
and other sparsely annotated GPCRs have typically used readouts that depend on the native 
or forced1 coupling of GPCRs with G proteins, e.g., Gs, Gi, Gq or G12 or 138–14. 
Unfortunately, these approaches are not well suited for the parallel and simultaneous 
genome-wide interrogation of the druggable GPCR-ome1. Alternatively, measurement of G-
protein independent β-arrestin recruitment provides a feasible and universal assay platform, 
since nearly all tested GPCRs can induce arrestin translocation15, 16 (Supplementary Table 
1). A wide variety of approaches has been described to quantify GPCR-β-arrestin 
interactions, including high content screening (HCS)17, bioluminescence resonance energy 
transfer (BRET)18, enzyme complementation19, and transcriptional activation following 
arrestin translocation (TANGO)20, although none are routinely performed in a genome-
wide, parallel manner. As we show here, the TANGO approach has a number of advantages 
for high throughput assays, including its independence from G protein coupling, generally 
high signal-to-background ratios, and its amplification of relatively small initial inputs into 
large readout signals. Independence from G protein coupling facilitates interrogation of 
orphan GPCRs, whose coupling partners are unknown. Some of the advantages of the 
TANGO assay might also be shared by other readout systems, including, for example, 
assays for changes in impedance or dynamic mass redistribution (reviewed in 21) and 
indeed, arrestin recruitment may be part of the dynamic mass redistribution response 
measured in receptor-expressing cells responding to agonists, as suggested, but not directly 
shown, by the results of Hennen et al22. Our goal was to develop the TANGO assay into a 
platform that could encompass the entire druggable GPCR-ome. Although our assay does 
not differ significantly in terms of the general concept from that of Barnea et al.20, several 
notable changes including the design of the plasmid constructs and assay execution have 
distinct advantages, as we describe below. We also demonstrate a method (PRESTO-
TANGO; Parallel Receptor-ome Expression and Screening via Transcriptional Output-
TANGO) that facilitates the rapid, efficacious, parallel, and simultaneous profiling of 
biologically active compounds across essentially the entire human druggable GPCR-ome. 
Additionally, we document how our approach leads to the facile identification of new 
synthetic and naturally-occurring agonists for orphan GPCRs. Finally, as our platform is 
open-source, our methods and reagents are made freely available to the scientific 
community.
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Our goal was to develop a platform suitable for the parallel and simultaneous interrogation 
of every non-olfactory druggable GPCR in the human genome. Accordingly, we devised a 
“modular” design strategy to produce a TANGO construct for each GPCR, extensively 
modifying the design of Barnea et al.20; the general scheme is shown in Figure 1a. The 
underlying principle was to make each GPCR construct in such a way that various 
“modules” could be conveniently included or excluded as desired (Fig. 1a). At the 5′-end, 
we included a cleavable signal sequence to promote membrane localization23 and a FLAG 
epitope tag in order to be able to monitor cell surface expression by immunohistochemistry. 
At the 3′-end, the sequences for the Tobacco Etch Virus nuclear inclusion a endopeptidase 
(TEV) cleavage site and the tetracycline transactivator (tTA) protein were exactly as 
published by Barnea et al.20. GPCR sequences were then codon-optimized for expression in 
human cell lines, and each receptor sequence was followed by sequence from the C-
terminus of the V2 vasopressin receptor (V2 tail) to promote arrestin recruitment20, 24–26. 
The receptor sequence and the V2 tail were flanked by restriction sites, allowing the facile 
excision from or subcloning of other targets into those sites, and more efficient gene 
synthesis. The codon-optimized sequences were designed to exclude their flanking 
restriction sites. Additionally, it should be noted that by simple mutagenesis to insert a 
“stop” codon at the 3′-end of the receptor sequence, these TANGO constructs can also be 
used in other functional assays, i.e., they can be “de-TANGO-ized”.
The sequence of an entire prototypical TANGO construct is given in Supplementary Note 1 
and the sequences of all of the receptor inserts produced can be found on-line at: (URL to be 
deposited upon manuscript acceptance). When multiple splicing isoforms existed for a given 
GPCR, the longest or the most prevalent form was used for the TANGO constructs. A few 
GPCRs with extremely long N-termini, and a few that could not be expressed in E. coli, 
were excluded from the project, resulting in a total of 315synthetic TANGO-ized GPCRs 
(Supplementary Table 2).
Validation of the PRESTO-TANGO platform
In preliminary experiments, each TANGO-ized construct was transfected and then examined 
by anti-FLAG immunofluorescence for both total and surface expression (Fig. 1b for 
examples). Of 315 constructs examined, 302 (96%) were surface-expressed (Supplementary 
Table 2). Of the remaining GPCRs that were not efficiently surface-expressed, receptor 
expression could be visualized in permeabilized cells (data not shown).
To test the utility of the platform, we assayed nearly all of the non-orphan receptors for 
activation by their canonical agonists. In total, we attempted to validate 167 non-orphan 
GPCRs and were successful with 125 (75%). Of the Family A GPCRs, 81% were validated, 
and these results are summarized in Table 1. Figures 1c and 1d show concentration-response 
curves for a prototypical non-orphan GPCR, the neuromedin B receptor (NMBR; also 
known as the BB1 bombesin receptor) for both β-arrestin recruitment activity (Fig. 1c) and 
G protein (calcium release) activity (Fig. 1d). Individual concentration-response curves for 
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every validated target are shown in Supplementary Data Set 1. Agonist-induced activation of 
the TANGO-ized GPCRs resulted in variable responses ranging from about 1.3-fold above 
baseline to 184-fold for the MLNR motilin receptor. Importantly, we discovered ligand-
induced arrestin recruitment for the first time in 23 different GPCRs, including the NMBR 
bombesin receptor (also known as BB1; Fig. 1c), the CHRM5 muscarinic acetylcholine 
receptor (Fig. 2a), the CX3CR1 chemokine receptor (Fig. 2b), the DRD4 dopamine receptor 
(Fig. 2c; this, despite reports that this target does not interact with arrestin27), the GAL3 
galanin receptor (Fig. 2d), the NMUR1 (Fig. 2e) and NMUR2 (Fig. 2f) neuromedin 
receptors, and others shown in Supplementary Data Set 1, including the AVPR1B 
vasopressin receptor, the CCKAR cholecystokinin receptor, the CMKOR1 orphan 
chemokine receptor, the GPBA bile acid receptor (but see also28), the HTR7 serotonin 
receptor, the LPAR5 lysophospholipid receptor (also known as GPR92), the MRGPRX4 
orphan receptor, the NTSR2 neurotensin receptor, the P2RY13 and P2RY14 purinergic 
receptors, the PTGER1 and PTGFR (but see also29) prostanoid receptors, the RXFP4 relaxin 
receptor, the S1PR2 lysophospholipid receptor, the SSTR4 somatostatin receptor (but see 
also30), and the TACR2 tachykinin receptor.
Additionally, we tested whether the antagonist activity of test compounds could be 
quantified by simply pre-incubating cells with potential antagonists before agonist exposure. 
Thus, for instance we, like others31, 32, found that neurotensin was inactive as an agonist at 
NTSR2 neurotensin receptors, although SR48692 and SR142948 are NTSR2 agonists 
(Supplementary Fig. 1a). Intriguingly, both neurotensin and the HRH1-histamine receptor 
antagonist levocabastine were antagonists of SR48692- or SR142948-induced arrestin 
recruitment responses in NTSR2-transfected cells (Supplementary Fig. 1b, c), as reported by 
others using orthogonal assays31, 32. Thus, these results validate the use of the TANGO β-
arrestin recruitment assay for measurements of antagonist activity.
As noted previously, the constructs tested included the C-terminal tail of the V2 vasopressin 
receptor (the “V2 tail”) in order to enhance arrestin interactions with the various 
receptors20, 25. Notably, the presence of the V2 tail has been reported to have little to no 
effect on the TANGO assay for some receptors24. In our experience, removal of the V2 tail 
had little effect on the ligand-induced responses of some receptors, e.g., the LTBR4 
leukotriene receptor (Supplementary Fig. 1d), increased the ligand-induced responses of 
others, e.g., the CMKLR1 chemerin receptor (Supplementary Fig. 1e), and decreased the 
ligand-induced responses of others, e.g., the FFAR2 free fatty acid receptor (GPR43; 
Supplementary Fig. 1f). A systematic and complete study of the effects of including or 
excluding the V2 tail remains to be done, though the results shown in Supplementary Figs 
1d–f provide a path forward for further optimization of the TANGO assay.
In additional experiments, we also validated the TANGO assay in “antagonist mode” by 
determining the effect of pre-exposure of GPCR-expressing cells to 1 μM clozapine on their 
responses to the agonist LSD. For some targets, clozapine had little or no effect on the 
responses of cells to LSD, e.g., the HTR1A and HTR1D serotonin receptors (Supplementary 
Fig. 2a, b). For others, e.g, the HTR1B serotonin receptor and the ADRA2B adrenergic 
receptor (Supplementary Fig. 2c, d), the major effect of clozapine on LSD concentration-
response curves was to shift them to the right. For still other GPCRs, e.g., the HTR1E, 
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HTR1F, HTR2A and HTR5 serotonin receptors, and the DRD2 dopamine receptor, the 
effect of clozapine was to both shift the curves to the right and to decrease the Emax 
(Supplementary Fig. 2e–i). These results therefore further validate the use of the TANGO β-
arrestin recruitment assay in “antagonist mode” and thus facilitate the discovery of novel 
modes of action of pharmacological agents.
Next, we tested each of the TANGO-ized constructs for constitutive activity, i.e., 
recruitment of arrestin in the absence of known ligands, as detailed in Methods, and as seen 
in Supplementary Figure 3, Supplementary Table 3 and Figures 3a and 53b Constitutive 
activity varied over a range of more than about 500-fold among the various GPCRs; in one 
set of GPCRs tested, the ratio of the maximal to the minimal luminescence was 437, and in 
another, the ratio was 551 (Supplementary Table 3; Figures 3a, b. Detailed analyses revealed 
no readily apparent sequence-encoded pattern when comparing GPCRs with high and low 
constitutive activity, although we note that several members of the serotonin and purinergic 
receptor families had relatively high constitutive activity compared to the other tested 
GPCRs.
We also discovered that although our standard protocols specify overnight incubation with 
ligands (see Methods), very brief exposures to ligand (i.e.., 15 min) are sufficient to 
stimulate measurable responses in the TANGO assay, although overnight incubation is 
apparently required for maximum signal amplification (Supplementary Fig. 4). This feature 
facilitates testing compounds that, in long exposures, may be toxic to cells, but in short 
exposures may reveal activity at GPCR targets. Additional studies (not shown) suggest that 
the minimum incubation time for robust observation of responses to agonists in the TANGO 
assay depends on the target being tested, but that, for screening purposes, one or two hours 
is generally sufficient, provided that the signal is amplified overnight. Thus, optimization of 
agonist exposure time may improve assay performance depending on the individual targets 
or ligands to be studied.
“Many target-few compound” parallel GPCR-ome screening
Conventional small-molecule based screening often involves testing of hundreds of 
thousands of compounds at a single target and, as we have demonstrated previously (https://
pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=588463), TANGO assays are useful for such 
conventional ‘one-target-at-a-time’ GPCR screening. An alternative and potentially 
innovative approach, which we have named “PRESTO-TANGO” (Parallel Receptor-ome 
Expression and Screening via Transcriptional Output-TANGO) is to screen collections of 
perturbants (e.g., small molecules, peptides, siRNAs, CRISPR-based editing constructs, and 
so on) against the druggable human GPCR-ome in a simultaneous fashion. Although 
simultaneous interrogation of the entire druggable GPCR-ome is clearly important, it has not 
been feasible for both technical and economic considerations. As we have developed a 
resource of most of the druggable GPCRs, we wondered if they could be screened in a 384-
well format in a simultaneous and parallel fashion (Fig. 4a; see Methods and Supplementary 
Note 2 for a detailed description of the technology). As an initial validation, we screened the 
hallucinogen lysergic acid diethylamide (LSD) and and the serotonin-selective reuptake 
inhibitor fluoxetine against 133 non-orphan, non-olfactory GPCR targets (Supplementary 
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Note 3). LSD displayed activity at 15 of the tested targets, including several unexpected 
ones such as the α2B adrenergic and the D4 and D5 dopamine receptors (Fig. 4b–d). 
Fluoxetine, which is reported to have few “off-targets”,33 showed modest agonist activity at 
the SSTR3 somatostatin receptor, which was not confirmed in follow-up assays (data not 
shown), thus supporting its selectivity for SERT and not for any GPCR targets.
Novel activities in the GPCR-ome
Given our initial success with two highly annotated small molecules and well-known 
GPCRs, we next determined if we could expand this approach by screening a collection of 
approved drugs (NIH Clinical Collection of compounds, NCC-1 library; http://
www.nihclinicalcollection.com) against 91 orphan and poorly annotated GPCRs. A heatmap 
of the results obtained is shown in Figure 5a, and the entire dataset is shown in 
Supplementary Table 4. As can be seen in Figure 5a and in Supplementary Table 4, some of 
the tested drugs displayed promiscuous inhibitory activity. Thus, for example, resveratrol 
produced a greater than 2-fold reduction at 70 of 91 (77%) and homoharringtonine at 58 of 
91 (64%) targets tested; twelve additional compounds produced a greater than 2-fold 
reduction in luminescence at 20 or more of the 91 targets tested. This sort of inhibition could 
be due to cytotoxicity, compound aggregation, or inhibition of the luciferase reporter34. In 
contrast, a few others -- most notably the aminopeptidase inhibitor bestatin (> 2-fold 
increase at 59 of 91 (65%) targets tested) -- induced increased activity. Although we did not 
investigate the mechanism for this promiscuous ‘agonist’ effect, such promiscuous activity 
has been previously ascribed to enhanced luciferase stability35, 36. These results illustrate the 
value of screening at multiple targets simultaneously and in a parallel fashion, enabling the 
separation of false positive “frequent hitters” from screening hits that can be productively 
pursued.
Among the most intriguing activities revealed by our screen of 446 compounds at 91 targets 
(i.e., 40,586 compound-target tests) was the activity of the KATP-channel blocker nateglinide 
at the MRGPRX4 orphan GPCR (Fig. 5b and Supplementary Table 4). Nateglinide induced 
a 45-fold increase in luminescence over basal levels in the initial screen and, of the 91 
targets tested, nateglinide was apparently selective for MRGPRX4 (Fig. 5b and 
Supplementary Table 4). The concentration-dependent activity of nateglinide at MRGPRX4 
was subsequently confirmed by TANGO (Fig. 5c) and PI hydrolysis assays (Fig. 5d). 
Nateglinide had exceedingly modest activity at high concentrations when cAMP was 
measured at MRGPRX4, and was inactive at MRGPRX1, MRGPRX2 or MRGPRX3 
(Supplementary Fig. 5a). The magnitude of the cAMP response was much lower than the 
response to isoproterenol in MRGPRX4-expressing cells, which is due to the responses of 
the constitutively expressed β2 adrenergic receptor in HEK cells (Supplementary Fig. 5b). 
These data, combined with the inability of nateglinide to inhibit a cAMP response to 
isoproterenol in these cells (Supplementary Fig. 5c), and the activity of nateglinide in the PI 
hydrolysis assay (Fig. 5d), indicate for the first time that MRGPRX4 is primarily a Gq-
coupled receptor. Next, we prepared stably expressing lines for MRGPRX1, MRGPRX2 and 
MRGPRX4 receptors; calcium mobilization assays done with these cell lines showed 
concentration-dependent responses of MRGPRX1-expressing cells to the cognate ligand 
BAM8-22 (Supplementary Fig. 6a, b), of MRGPRX2-expressing cells to SB 205,607 
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(Supplementary Fig. 6c, d), and of MRGPRX4-expressing cells to nateglinide 
(Supplementary Fig. 6e, f), further indicating that this group of receptors is primarily Gq-
coupled in HEK cells.
In preliminary screening studies, we also identified the HIV protease inhibitor saquinavir as 
a potential agonist at an orphan GPCR, the so-called BB3 bombesin receptor. To further 
investigate saquinavir’s BB3 activity, and validate the specificity of our platform, we 
confirmed its concentration-dependence at BB3 (Fig. 5e), and showed that the related 
bombesin receptors BB1 (Supplementary Fig. 7a) and BB2 (Supplementary Fig. 7b) were 
insensitive to saquinavir in the TANGO assay. In orthogonal calcium mobilization assays, 
saquinavir did not stimulate a response in BB1- or BB2-expressing cells (Supplementary 
Fig. 7c, 7d), but did stimulate a response in BB3-expressing cells (Supplementary Fig. 7e), 
and this activity was also confirmed by an assay of PI hydrolysis (Fig. 5f). Thus, these data 
confirm that saquinavir has significant off-target activity at the BB3 orphan GPCR, and 
serve to validate that the apparent target specificity of the TANGO assay can be 
recapitulated in orthogonal assays.
Our initial screen of the NCC-1 library also included the related target MRGPRX2 
(Supplementary Table 4), at which the most active compounds included the delta opioid 
receptor agonist SB 205,607 (also known as TAN-67), confirming a prior report37. 
Interestingly, two other opioids, levorphan and dextromethorphan, as well as the 
antihistaminergic and antiserotonergic compound cyproheptadine, the antihistaminergic 
compound ketotifen, and the antiserotonergic compound pizotyline, also showed activity in 
the TANGO assay at MRGPRX2 (Supplementary Table 4)—all of which were confirmed in 
concentration-response studies (Supplementary Fig. 8a). The concentration-dependent 
activities of SB 205,607 and dextromethorphan at MRGPRX2 were also confirmed by PI 
hydrolysis (Supplementary Fig. 8b). An intriguing discovery was the finding that the kappa 
opioid receptor selective antagonist JDTic and the selective salvinorin A analogue RB64 
displayed significant activity at MRGPRX2 in the TANGO assay (Supplementary Fig. 8c).
DISCUSSION
Here we provide the first open-source resource, which we have named PRESTO-TANGO, 
for the parallel and simultaneous interrogation of the druggable GPCR-ome, as summarized 
in Figure 6 The development of this unique platform was facilitated by modifying and 
expanding an arrestin recruitment (TANGO) assay20 for GPCR activation that is sensitive, 
easily executed, and amenable to both HTS and simultaneous parallel screening at many 
GPCRs. Since knowledge of the G protein partners of each GPCR is not required, this assay 
is particularly suitable for “first-pass” screening of compound libraries and for identifying 
ligands of orphan receptors, as has been previously suggested20, 37. Importantly, we have 
demonstrated that: (i) activation of the majority of GPCRs can be measured using the 
TANGO arrestin recruitment assay; (ii) the TANGO assay can also be used for measurement 
of antagonist activity when canonical or newly discovered agonists are available; and (iii) 
the simultaneous parallel screening of a few compounds using the PRESTO-TANGO 
approach, or the parallel screening of compound libraries using the TANGO method, reveals 
new activities for known drugs and compounds, and identifies new ligands for both sparsely 
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annotated and orphan GPCRs. Although the TANGO β-arrestin recruitment assay has 
previously been used by many others, including us for the DRD2 dopamine receptor38, the 
DOR39 and KOR40, 41 opioid receptors, and several serotonin receptors42, the present study 
is the first to adapt it to almost the entire GPCR-ome, and to make the entire resource 
publicly available to the scientific community. This resource is thus likely to find 
widespread use by structural biologists who focus on GPCRs, chemical biologists intent on 
deconstructing the actions of drug-like compounds, molecular biologists searching for 
GPCR perturbants, molecular pharmacologists and systems biologists.
Although this unique resource and the overall approach we used are both quite powerful, the 
resource is currently limited by our inability to validate assays for some GPCRs. Why assays 
for these particular GPCRs (see Fig. 6) could not be validated remains largely unknown, 
although it is likely that upon further optimization, useful assays for many of these can be 
perfected. Alternatively, it is conceivable that some receptors do not interact with arrestins 
in an agonist-dependent fashion, as has been claimed for the α1A adrenergic receptor 
(ADRA1A)43, the AT2 angiotensin II receptor (AGTR2)44, and the D4 dopamine receptor 
(DRD4)(see 27 for example). Indeed, for the β3 adrenergic (ADRB3) receptor, which lacks 
the consensus sequences for GRK phosphorylation and thus for arrestin binding, 
downstream signaling appears to proceed by direct interaction with kinases in the ERK 
pathway.45 For other GPCRs, for which receptor-arrestin interactions have been reported in 
the literature (Supplementary Table 1) but for which we were not able to initially validate 
assays, it may be that the TANGO assay requires further optimization, perhaps by removal 
of the V2 tail, or that the other arrestin recruitment assays used in the literature are more 
tractable than the TANGO assay for these particular GPCRs. Interestingly, there were also a 
few targets for which the TANGO assay proved suitable, although there had been reports in 
the literature that these targets did not interact with arrestin – these included the GPBA bile 
acid receptor28, the prostaglandin F2α (PTGFR) receptor29, the SSTR4 somatostatin 
receptor30, and the aforementioned DRD4-dopamine receptor. It is also possible that some 
of the targets that could not be validated in our study interact with other members of the 
arrestin family, but not the β-arrestin2 as used here. In order to adapt our realization of the 
TANGO assay to interactions with other members of the arrestin family, all that would be 
required would be the creation of a cell line expressing alternative β-arrestins. Importantly, 
our validation studies revealed several agonist-induced receptor-arrestin interactions for the 
first time; these included at least 23 different receptor targets (see Table 1 and 
Supplementary Data Set 1). Finally, and importantly, for some GPCR targets, these assays 
are the first reliable functional assays for receptor activation to be reported, e.g., the HTR5 
serotonin receptor. All of the validated TANGO assays, and all of those that could not be 
validated, are summarized in Supplementary Table 5.
In addition to providing a resource for testing the function of nearly the entire druggable 
human GPCR-ome, we have also devised a method by which one or a few compounds can 
be tested at all 315 GPCR targets simultaneously and in parallel. Our preliminary results, in 
which we tested two compounds against 133 targets, showed novel activities for a well-
known compound, LSD, and verified the relative selectivity of the SSRI fluoxetine. Such 
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simultaneous and parallel screening also facilitates the identification of promiscuous 
compounds (i.e., “frequent hitters”), thereby minimizing futile follow-up studies.
We also screened a small library of US FDA-approved drugs at 91 different GPCR targets 
using the TANGO platform. Our intention was: (i) to discover ligands at poorly annotated or 
“orphan” receptors: (ii) to discover new targets for known drugs; (iii) to test whether the 
activity of compounds in the TANGO assay could be confirmed in orthogonal assays; and 
(iv) to demonstrate the value of massively parallel screening to separate promiscuous 
compounds from novel ligand-receptor pairs. Among the most striking results from this 
screen (Fig. 5b–d, Supplementary Table 4) was the remarkable activity shown by the 
diabetes drug nateglinide, a KATP channel blocker, at MRGPRX4, a member of the MAS-
related GPCR family. There are four MRGPRX receptors in the human genome and they 
have been reported to be expressed only in primates, with expression largely limited to the 
dorsal horn of the spinal cord (reviewed by 46). For the most part, the MRGPRX family is 
thought to be peptidergic, although a few small molecule ligands are also reported46. Based 
on analogy with the larger family of MAS-related GPCRs that has been extensively studied 
in rodents, MRGPRX receptors are thought to have a role in pain and itch46. Thus, it is 
interesting that the itch-inducing compound chloroquine activates MAS-related GPCRs in 
mice47, and that there are reports of “rash, itching and urticaria” as occasional side-effects of 
nateglinide treatment48. Our initial screen of the NCC-1 library also revealed a large number 
of compounds belonging to a variety of pharmacological classes that were active at 
MRGPRX2, including the delta opioid receptor agonist SB 205,607 (also known as 
TAN-67), as previously reported37. Some other opioid receptor ligands were also active at 
MRGPRX2, which may reflect the role of similar receptors in pain46. Many other potential 
ligand-orphan GPCR pairings were identified in the initial screen and will be important to 
pursue in subsequent studies.
Importantly, the results of our validation studies demonstrate that our approach facilitates 
the simultaneous profiling of hundreds of GPCRs in a cost-effective and robust manner. 
Additionally, as many novel GPCR-ligand interactions are revealed, we have begun to 
illuminate a previously unknown and subterranean pharmacology for known drugs and new 
ligands at orphan and non-orphan GPCRs. As this is an open-source resource, (ADDGENE 




All transfections were done using an optimized calcium phosphate method.49
“Standard” arrestin recruitment assay
HTLA cells, (an HEK293 cell line stably expressing a tTA-dependent luciferase reporter and 
a β-arrestin2-TEV fusion gene) were a gift from the lab of Richard Axel, and were 
maintained in DMEM supplemented with 10% FBS, 2 μg/ml puromycin and 100 μg/ml 
hygromycin B in a humidified atmosphere at 37°C in 5% CO2. For transfection, cells were 
plated at 9 to 10 × 106 cells per 150 mm cell culture dish (day 1). The following day (day 2), 
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cells were transfected using the calcium phosphate method. On day 3, transfected cells were 
transferred at 15,000 to 20,000 cells per well in 40 μl of medium into poly-L-lysine coated 
and rinsed 384-well white clear-bottom cell culture plates (Greiner Bio-one). On day 4, 3.5x 
drug stimulation solutions were prepared in filter-sterilized assay buffer, which consisted of 
20 mM HEPES and 1x HBSS at pH 7.4, and 20 μl added to each well. On day 5, medium 
and drug solutions were removed from the wells (by aspiration or shaking), and 20 μl per 
well of Bright-Glo solution (Promega) diluted 20-fold in assay buffer were added to each 
well. After incubation for 15 to 20 minutes at room temperature, luminescence was counted 
in a Trilux luminescence counter. Results in the form of RLU (relative luminescence units) 
were exported into Excel spreadsheets, and Graphpad Prism was used for analysis of data. 
To measure constitutive activity, no ligand was added on day 4.
PRESTO-TANGO GPCR-ome screening β-arrestin recruitment assay
see Supplementary Text File 2.
Immunofluorescence
On day 1, cells (15,000/well in 384-well clear-bottom black plates) were prefixed with 4% 
paraformaldehyde (PFA) for 30 min at RT, incubated with anti-FLAG antibody (1:500, 
polyclonal rabbit anti-Flag, Sigma #F1804), and incubated for 1 hour at room temperature 
and then overnight at 4°C. On day 2, cells were incubated with Alexa Fluor 594-conjugated 
goat anti-rabbit antibody (1:200, Invitrogen) and nuclear dye (Hoechst 33342, 1:2000, 
Invitrogen) for 1 hour at RT in the dark. After thorough washing with PBS (1X PBS, 0.5 
mM CaCl2, pH 7.4), cells were post-fixed with 4% PFA for 30 min on ice and stored at 4 °C 
in the dark. Images were obtained using the BD Pathway Bioimaging System (BD).
PI hydrolysis
HEK-293T cells were maintained in DMEM supplemented with 10% fetal bovine serum 
(FBS), 100 IU/ml penicillin and 100 μg/ml streptomycin. Cells were transfected with 10 μg 
of receptor DNA per 15 cm cell culture dish and incubated overnight at 37°C in a 
humidified 5% CO2; the next day, cells were seeded into poly-L-lysine coated 96-well plates 
in 200 μl per well of DMEM supplemented with 1% dialyzed FBS, 100 IU/ml penicillin and 
100 μg/ml streptomycin. After attaching to the plate, cells were incubated for 16 hours as 
above in inositol-free DMEM (United States Biological, Swampscott, MA) containing 1% 
dialyzed FBS, and 1 μCi/well of 3H-inositol. Next, cells were washed with 100 μl drug 
buffer (1X HBSS, 24 mM NaHCO3, 11 mM glucose, 15 mM LiCI, pH 7.4) and treated with 
100 μl of drug buffer containing 10 μM drug in quadruplicate for 1 hour at 37°C in a 5% 
CO2 incubator. Alternatively, for concentration-response curves, cells were treated with a 
range of concentrations in quadruplicate in 100 μl of drug buffer and incubated for 1 hour at 
37°C in a 5% CO2 incubator. Following treatment, drug solution was removed and 40 μl of 
50 mM formic acid was added to lyse cells for 30 minutes at 4°C. After cell lysis, 40 μl of 
acid extracts were transferred to polyethylene terephthalate 96-well sample plate 
(PE#1450-401) and mixed with 75 μl of Perkin Elmer RNA Binding YSi SPA Beads 
(#RPNQ0013) at a concentration of 0.2 mg beads/well and incubated for 30 minutes at 4°C. 
Bead/lysate mixtures were then counted using a Perkin Elmer 2450 MicroPlate Counter.
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Cells were plated (15,000 cells/well) into poly-L-lysine coated 384-well clear-bottom black-
walled microplates (Greiner Bio-one) with 40 μl of media (DMEM media supplemented 
with 500 ug/ml geneticin sulfate (G-418), 1% dialyzed fetal bovine serum, and 50 U of 
penicillin/50 μg of streptomycin) and incubated overnight (37 °C, 5% CO2). The following 
day, media was replaced with 20 μl of calcium dye (FLIPR Calcium 4 Assay Kit; Molecular 
Devices) diluted in assay buffer (1x HBSS, 2.5 mM probenecid, 20 mM HEPES, pH 7.4–
7.8) and incubated for 45 min at 37 °C and 15 min at room temperature. Compounds were 
initially dissolved in DMSO at 10 mM. The 16-point curves were prepared as 3x serial 
dilutions for each compound with final concentrations ranging from 10 μM to 0.003 nM. 
Basal fluorescence was measured for 10 s, then 10 μl of test or control compounds were 
added, followed by continued fluorescence measurement for an additional 120 s. Raw data 
was plotted as a function of molar concentration of test compound using Prism 5.0 
(GraphPad Software).
Generation of stable cell lines
Inducible cell lines expressing MRGPRX1, MRGPRX2 or MRGPRX4 were generated using 
the Flp-In T-Rex Core Kit (Invitrogen) according to the manufacturer’s instructions. In 
brief, genes were subcloned into the pcDNA5/FRT/TO vector and cotransfected with the 
POG44 expression plasmid into the Flp-In T-Rex HEK-T cell line using FuGENE HD 
transfection reagent (Promega). Receptor-expressing cells were selected and maintained in 
DMEM containing 10% FBS, 15 μg/ml blasticidin, 100 μg/ml hygromycin B, and 100 IU 
Penicillin and 100 μg/ml Streptomycin. Receptor expression following 24 hours of 1ug/ml 
Tetracycline treatment was confirmed via immunofluorescence with an anti-FLAG antibody 
(Sigma #F1804) as above.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Design, principle, and validation of selected TANGO assays
(a) Modular design of TANGO constructs (top); blue arrowheads indicate Cla I sites, and 
green arrowheads indicate Age I sites. General scheme for the β-arrestin (TANGO) 
recruitment assay (bottom). Upon activation of the GPCR by an agonist (1), β-arrestin is 
recruited to the C-terminus of the receptor (2). This is followed by cleavage of the GPCR 
fusion protein at the TEV protease site (3). Cleavage results in the release of the tTA 
transcription factor (4), which, after transport to the nucleus, activates transcription of the 
luciferase reporter gene (5). (b) Surface expression of two selected TANGO constructs as 
shown by immunofluorescence using an anti-FLAG antibody. Concentration-response 
curves of a prototypical non-orphan GPCR, the neuromedin B receptor stimulated by 
neuromedin B (NMB) in the TANGO assay (c) and in a calcium-release assay (d); data are 
shown as the mean ± SEM of typical experiments done in quadruplicate. Curves were fitted 
using Graphpad Prism 5.0.
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Figure 2. First-time demonstration of arrestin mobilization using the TANGO assay
Shown are concentration-response curves for the response of (a) the CMRM5 muscarinic 
acetylcholine receptor to carbachol (EC50 = 133.8 nM, n = 4), (b) the CX3CR1 chemokine 
receptor to its ligand CX3CL1 (EC50 = 0.34 nM, n = 4), (c) the DRD4 dopamine receptor to 
lisuride (EC50 = 2.0 nM, n = 3), (d) the GAL3 galanin receptor to galanin (EC50 = 0.13 nM, 
n = 4), (e) the NMUR1 neuromedin receptor to neuromedin S (EC50 = 10.2 nM, n = 4), and 
(f) the NMUR2 neuromedin receptor to neuromedin S (EC50 = 15.4 nM, n = 4).
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Figure 3. Constitutive (or basal) activity for TANGO-ized constructs
Data are expressed in RLU (relative luminescence units) for the orphan and peptide GPCRs 
(a) and the non-orphan (b) GPCRs (n = 4 for each target.
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Figure 4. Compound profiling using the PRESTO-TANGO method at the human GPCR-ome
(a) General format in which compounds are screened against a large number of GPCRs in 
quadruplicate in 384-well plates; for clarity only the first row of individual GPCRs is shown. 
(b–d) Concentration-response curves of LSD at various targets; data are shown as mean ± 
SEM, and curves were fitted with Graphpad Prism. (b) DRD4-dopamine, (c) DRD5-
dopamine, (d) ADRA2B-adrenergic.
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Figure 5. Novel ligand-target interactions detected by parallel GPCR-ome screening
Results of screening of the 446-compound NCC-1 library at 91 GPCR targets in the 
TANGO assay, and follow-up studies are shown. (a) Heatmap of the entire matrix (red = 
stimulation of luminescence over background). (b) Closeup view of a section of the 
heatmap, showing the activity of nateglinide at MRGPRX4. (c) Concentration-response 
curve of nateglinide at MRGPRX4 in the TANGO assay (n = 4). (d) Concentration-response 
curve of nateglinide at MRGPRX4 by PI hydrolysis (n = 3). (e) Concentration-response 
curve of saquinavir at the BB3 bombesin receptor in the TANGO assay (n = 4). (f) 
Concentration-response curve of saquinavir at the BB3 bombesin receptor by PI hydrolysis 
(n = 3).
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Fig. 6. TANGO-izing the druggable GPCR-ome
Tree-based phylogram of the non-olfactory GPCR-ome showing the status of the TANGO 
assay for each GPCR. Cyan circles represent those non-orphan GPCRs for which assays 
were validated; yellow circles represent those assays for which expression of orphan GPCRs 
were validated; blue circles represent those non-orphan GPCRs for which optimized assays 
are not yet available, and black circles represent those GPCRs for which no TANGO-ized 
construct is available.
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